NKTCL
MCID: NSL029
MIFTS: 40

Nasal Type Extranodal Nk/t-Cell Lymphoma (NKTCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Nasal Type Extranodal Nk/t-Cell Lymphoma

MalaCards integrated aliases for Nasal Type Extranodal Nk/t-Cell Lymphoma:

Name: Nasal Type Extranodal Nk/t-Cell Lymphoma 12
Nasal T/natural Killer-Cell Lymphoma 20 58
Extranodal Nasal Nk/t Cell Lymphoma 20 58
Angiocentric T-Cell Lymphoma 20 58
Lethal Midline Granuloma 20 58
Nk/t-Cell Lymphoma 20 58
Nktcl 20 58

Characteristics:

Orphanet epidemiological data:

58
extranodal nasal nk/t cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080797
NCIt 50 C4684
ICD10 32 C86.0
MESH via Orphanet 45 D054391
ICD10 via Orphanet 33 C86.0
UMLS via Orphanet 72 C0018197 C0392788
Orphanet 58 ORPHA86879

Summaries for Nasal Type Extranodal Nk/t-Cell Lymphoma

GARD : 20 Extranodal nasal NK/T cell lymphoma (NKTCL) is a rare type of cancer. The term extranodal is used because this form of lymphoma is found outside of the traditional lymph node groupings. It mainly affects men around 50 years of age, and usually arises in the nose, paranasal sinuses (paranasal sinuses are cavities (spaces) or small tunnels. located around or near the nose), orbits or upper airway, and that can present with a nasal mass, nasal bleeding, nasal obstruction, a hole in the palate, and mid-facial and/or upper airway destructive lesions. In advanced disease stages, which are associated with a poor prognosis, NKTCL may affect other organs, but usually without enlarged nodes in the body. The treatment depends on the extent of disease and usually involves radiotherapy and chemotherapy.

MalaCards based summary : Nasal Type Extranodal Nk/t-Cell Lymphoma, also known as nasal t/natural killer-cell lymphoma, is related to lethal midline granuloma and mature t-cell and nk-cell lymphoma. An important gene associated with Nasal Type Extranodal Nk/t-Cell Lymphoma is KLRC1 (Killer Cell Lectin Like Receptor C1), and among its related pathways/superpathways are Allograft rejection and Immune response Role of DAP12 receptors in NK cells. The drugs Mechlorethamine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include t cells, lymph node and liver.

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma that is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.

Related Diseases for Nasal Type Extranodal Nk/t-Cell Lymphoma

Diseases related to Nasal Type Extranodal Nk/t-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 lethal midline granuloma 11.9
2 mature t-cell and nk-cell lymphoma 10.8
3 lymphoma 10.7
4 cellulitis 10.6
5 polymorphic reticulosis 10.6
6 rare tumor 10.5
7 pancytopenia 10.5
8 splenomegaly 10.5
9 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.4
10 aggressive nk-cell leukemia 10.4
11 thrombocytopenia 10.4
12 crohn's disease 10.4
13 lymphoma, hodgkin, classic 10.4
14 lymphoma, non-hodgkin, familial 10.4
15 neutropenia 10.4
16 allergic disease 10.4
17 histiocytosis 10.4
18 47,xyy 10.4
19 dysphagia 10.4
20 fibrosarcoma of bone 10.3
21 graft-versus-host disease 10.3
22 hemophagocytic lymphohistiocytosis 10.3
23 leukemia 10.3
24 toxic shock syndrome 10.3
25 pneumonia 10.3
26 lymphomatoid granulomatosis 10.3
27 rheumatoid arthritis 10.3
28 aspergillosis 10.3
29 t-cell lymphoma, subcutaneous panniculitis-like 10.3
30 hyperglycemia 10.3
31 arthritis 10.3
32 epstein-barr virus-related tumor 10.3
33 ataxia and polyneuropathy, adult-onset 10.3
34 nasopharyngeal carcinoma 10.3
35 crohn's colitis 10.3
36 respiratory failure 10.3
37 orbital cellulitis 10.3
38 uveitis 10.3
39 lymphadenitis 10.3
40 glomerulonephritis 10.3
41 pyoderma 10.3
42 lung lymphoma 10.3
43 pyoderma gangrenosum 10.3
44 hydroa vacciniforme 10.3
45 burkitt lymphoma 10.2
46 mantle cell lymphoma 10.2
47 mucositis 10.2
48 lipid metabolism disorder 10.2
49 paresthesia 10.2
50 peripheral t-cell lymphoma 10.2

Graphical network of the top 20 diseases related to Nasal Type Extranodal Nk/t-Cell Lymphoma:



Diseases related to Nasal Type Extranodal Nk/t-Cell Lymphoma

Symptoms & Phenotypes for Nasal Type Extranodal Nk/t-Cell Lymphoma

Drugs & Therapeutics for Nasal Type Extranodal Nk/t-Cell Lymphoma

Drugs for Nasal Type Extranodal Nk/t-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
2
Etoposide Approved Phase 4 33419-42-0 36462
3 BB 1101 Phase 4
4 Protective Agents Phase 4
5 HIV Protease Inhibitors Phase 4
6
protease inhibitors Phase 4
7 Histone Deacetylase Inhibitors Phase 4
8 Angiogenesis Inhibitors Phase 4
9 Immunoglobulins Phase 4
10 Antibodies Phase 4
11 Etoposide phosphate Phase 4
12 Antibodies, Blocking Phase 4
13
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
14
leucovorin Approved Phase 3 58-05-9 6006
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Antirheumatic Agents Phase 3
17 Anti-Bacterial Agents Phase 3
18 Dermatologic Agents Phase 3
19 Vitamin B Complex Phase 3
20 Folic Acid Antagonists Phase 3
21 Folate Phase 3
22 Vitamin B9 Phase 3
23 Calcium, Dietary Phase 3
24
Calcium Nutraceutical Phase 3 7440-70-2 271
25
Lenograstim Approved, Investigational Phase 2 135968-09-1
26
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
27
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
29
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
30
Melphalan Approved Phase 2 148-82-3 4053 460612
31
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
32
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
33
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
34
Pegaspargase Approved, Investigational Phase 2 130167-69-0
35
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
36
Busulfan Approved, Investigational Phase 2 55-98-1 2478
37
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
38
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
39
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
40
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
41
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
42
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
43
Lenalidomide Approved Phase 2 191732-72-6 216326
44
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
45
Basiliximab Approved, Investigational Phase 2 179045-86-4, 152923-56-3
46
Tofacitinib Approved, Investigational Phase 2 477600-75-2
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Durvalumab Approved, Investigational Phase 2 1428935-60-7
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
rituximab Approved Phase 2 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
2 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
3 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Recruiting NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
4 A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Recruiting NCT04490590 Phase 4 Chidamide+ Etoposide
5 A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) Recruiting NCT04365036 Phase 3 Toripalimab;Pegaspargase;Gemcitabine;Oxaliplatin
6 The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
7 PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients:a Randomized, Open-label, Phase 3 Study Active, not recruiting NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
8 An Open-Label, Uncontrolled, Single Centered Phase Ⅱ Study of Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone (Avastin+ GemAOD) As First-Line Treatment in Patients With Untreated NK/T Cell Lymphoma Unknown status NCT01921790 Phase 2 Gemcitabine;Oxaliplatin;Pegaspargase;Dexamethasone
9 An Open, Single-center, Phase II Clinical Trial for Treatment of Untreated Extranodal NK/T Cell Lymphoma With High Dose of Methotrexate in Combination With Gemcitabine, Pegaspargase and Dexamethasone (GAD-M Regimen) Unknown status NCT01991158 Phase 2 High dose of methotrexate;Gemcitabine;Pegaspargase;Dexamethasone
10 A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Latent Membrane Protein-2a [LMP2A] Specific Eutil Autologous Blood-derived T Lymphocytes) in Patients With Progressive Epstein-Barr Virus (EBV) Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed Unknown status NCT03789617 Phase 1, Phase 2
11 A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma Unknown status NCT01667302 Phase 2 Radiotherapy followed by chemotherapy
12 Single-arm, Open and Multi-center Phase II Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Unknown status NCT03776279 Phase 2 Mitoxantrone Hydrochloride Liposome Injection
13 Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma Unknown status NCT00568607 Phase 2 IFO, VP-16, DDP, DXM
14 Mild-dose Intensity-modulated Radiation Treatment for Stage IE/IIE Extranodal Nasal-type NK/T-cell Lymphoma With Complete Remission Tumor After Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) Chemotherapy:a Phase II Study Unknown status NCT02229682 Phase 2
15 Phase II Study of L-asparaginase Plus DICE Regimen in Patients With Stage I/II NK/T-cell Lymphoma Unknown status NCT00933673 Phase 2 L-asp, DXM, IFO, VP-16, DDP
16 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
17 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
18 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
19 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
20 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
21 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
22 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
23 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
24 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01238159 Phase 2
25 Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Patients With Unfavorable Prognostic Factors: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT02276248 Phase 2 GDP chemotherapy
26 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01007526 Phase 2
27 A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-cell Lymphoma Completed NCT00292695 Phase 2
28 A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma Completed NCT00418535 Phase 2 Concurrent Radiotherapy (RT)/cisplatin, VIPD
29 Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma Completed NCT00283985 Phase 2 Kidrolase;Methotrexate;Dexamethasone;Erwinase
30 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
31 Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4) Completed NCT03228836 Phase 2 Sintilimab
32 Phase II Study of L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma Completed NCT00854425 Phase 2 L-asparaginase
33 A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade
34 Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
35 The Efficacy and Safety of Anti-PD-1 Antibody in Combination With Pegaspargase in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT04096690 Phase 2 Pegaspargase;Anti-PD-1 monoclonal antibody
36 Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma Recruiting NCT02544425 Phase 2 Etoposide;Ifosfamide;Dexamethasone;L-asparaginase;Busulfan;Melphalan
37 Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type), a Multicenter, Open-label Phase Ib/II Trial Recruiting NCT04602065 Phase 1, Phase 2 IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
38 Combination of Lenalidomide and Sintilimab for Patients With Relapsed/Refractory NK/T-cell Lymphoma Who Failed Pegaspargase-based Regimens: a Single Arm, Open, Phase II Study Recruiting NCT04231370 Phase 2 Sintilimab;Lenalidomide
39 Sintilimab With P-GemOx (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (ENKTL): a Single Arm, Open, Multicenter, Phase II Study Recruiting NCT04127227 Phase 2 sintilimab,pegaspargase,gemcitabine,oxaliplatin
40 Combination of Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study Recruiting NCT04279379 Phase 2 Sintilimab;Decitabine
41 Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma Recruiting NCT03246750 Phase 1, Phase 2 B-MAD chemotherapy
42 A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients Recruiting NCT03671850 Phase 2
43 Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type Recruiting NCT03728972 Phase 2 Pembrolizumab
44 A Prospective Phase II Study of Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Patients With Newly Diagnosed Extra-nodal NK/T-cell Lymphoma Recruiting NCT04484506 Phase 2 pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone
45 An Open-label, Single-arm, Global Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Recruiting NCT04414163 Phase 2 IMC-001
46 Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study Recruiting NCT04405375 Phase 2 gemcitabin;Pegaspargase;Etoposide;Dexamethasone
47 Phase 2 Trial of PEG-ASP Combined With Etoposide and Gemcitabine (PEG) as First-line Chemotherapy to Treat NK/T-cell Lymphoma Recruiting NCT02705508 Phase 2 Gemcitabine;etoposide;Pegaspargase
48 A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody (Sintilimab) in Combination With Pegaspargase and Erlotinib in the Treatment of Stage IV Extranodal NK/T-cell Lymphoma Unfit for High-intensity Chemotherapy Recruiting NCT04004572 Phase 2 LEAP regimen
49 An Open, Multi-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma Recruiting NCT03936452 Phase 2 Sintilimab
50 Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas Recruiting NCT02859402 Phase 2 Busulfan;Fludarabine

Search NIH Clinical Center for Nasal Type Extranodal Nk/t-Cell Lymphoma

Genetic Tests for Nasal Type Extranodal Nk/t-Cell Lymphoma

Anatomical Context for Nasal Type Extranodal Nk/t-Cell Lymphoma

MalaCards organs/tissues related to Nasal Type Extranodal Nk/t-Cell Lymphoma:

40
T Cells, Lymph Node, Liver, Skin, Bone Marrow, Thyroid, Prostate

Publications for Nasal Type Extranodal Nk/t-Cell Lymphoma

Articles related to Nasal Type Extranodal Nk/t-Cell Lymphoma:

(show top 50) (show all 202)
# Title Authors PMID Year
1
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. 61
33588922 2021
2
Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population. 61
33242451 2021
3
Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway. 61
33423158 2021
4
Nasal-type extranodal NK/T-cell lymphoma: a diagnostic challenge. 61
33514618 2021
5
Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation. 61
32815763 2020
6
Calreticulin increases growth and progression of natural killer/T-cell lymphoma. 61
33221760 2020
7
[Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma]. 61
33333695 2020
8
m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. 61
33205540 2020
9
Involvement of miR-142 and miR-155 in Non-Infectious Complications of CVID. 61
33081305 2020
10
Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma. 61
32925768 2020
11
MTMR2 promotes the progression of NK/T cell lymphoma by targeting JAK1. 61
32767332 2020
12
Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study. 61
32872045 2020
13
Intestinal NK/T cell lymphoma: A case report. 61
32774072 2020
14
Identification of a peptide targeting CD56. 61
32747027 2020
15
Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIγ-c-Myc signaling pathway. 61
32641029 2020
16
Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. 61
32333152 2020
17
Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma. 61
32617308 2020
18
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. 61
32296914 2020
19
Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma. 61
32298986 2020
20
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma. 61
32004387 2020
21
Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma. 61
31764026 2020
22
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. 61
32183952 2020
23
Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma. 61
32183945 2020
24
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. 61
31879220 2020
25
Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma. 61
32850435 2020
26
Aggressive natural killer/T-cell lymphoma masquerading as acute orbital hemorrhage: a case report. 61
32509082 2020
27
Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. 61
32127923 2020
28
Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma. 61
31441360 2020
29
Oncogenic Network and Hub Genes for Natural Killer/T-Cell Lymphoma Utilizing WGCNA. 61
32195177 2020
30
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. 61
30940492 2020
31
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review. 61
33363038 2020
32
Nasal-type extranodal natural killer/T-cell lymphoma presenting with a mass on the buttock: A case report. 61
31804361 2019
33
[Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma]. 61
31770855 2019
34
Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era. 61
31298062 2019
35
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). 61
31060406 2019
36
Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma. 61
31724562 2019
37
Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience. 61
30971067 2019
38
Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases. 61
31623372 2019
39
Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type. 61
30940744 2019
40
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. 61
31527657 2019
41
c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. 61
30825244 2019
42
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. 61
31001658 2019
43
Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. 61
31124291 2019
44
Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. 61
30546078 2019
45
What we should know about natural killer/T-cell lymphomas. 61
31187536 2019
46
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. 61
30821826 2019
47
Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. 61
30827933 2019
48
Primary adrenal extranasal NK/T cell lymphoma with subcutaneous involvement demonstrated on FDG PET/CT: A clinical case report. 61
30882662 2019
49
[Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension]. 61
30678418 2019
50
The aberrant activation of Wnt pathway caused by β-catenin mutation and its prognostic significance in NK/T-cell lymphoma. 61
30509083 2019

Variations for Nasal Type Extranodal Nk/t-Cell Lymphoma

Expression for Nasal Type Extranodal Nk/t-Cell Lymphoma

Search GEO for disease gene expression data for Nasal Type Extranodal Nk/t-Cell Lymphoma.

Pathways for Nasal Type Extranodal Nk/t-Cell Lymphoma

Pathways related to Nasal Type Extranodal Nk/t-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.67 TNFSF13B KLRD1 KLRC3 KLRC1
2
Show member pathways
11.61 KLRD1 KLRC3 KLRC1
3 11.39 KLRD1 KLRC1
4 10.8 KLRD1 KLRC1

GO Terms for Nasal Type Extranodal Nk/t-Cell Lymphoma

Cellular components related to Nasal Type Extranodal Nk/t-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.62 KLRD1 KLRC1

Biological processes related to Nasal Type Extranodal Nk/t-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.33 TNFSF13B KLRD1 KLRC1
2 cell surface receptor signaling pathway GO:0007166 9.26 KLRD1 KLRC1
3 negative regulation of natural killer cell mediated cytotoxicity GO:0045953 8.96 KLRD1 KLRC1
4 negative regulation of T cell mediated cytotoxicity GO:0001915 8.62 KLRD1 KLRC1

Molecular functions related to Nasal Type Extranodal Nk/t-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.43 KLRD1 KLRC3 KLRC1
2 carbohydrate binding GO:0030246 9.33 KLRD1 KLRC3 KLRC1
3 protein antigen binding GO:1990405 8.96 KLRD1 KLRC1
4 MHC class I protein complex binding GO:0023024 8.62 KLRD1 KLRC1

Sources for Nasal Type Extranodal Nk/t-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....